Pulmonary Arterial Pressure Above 30 mmHg Linked to Increased...
2019年7月8日 · Read about an Australian study suggesting that a pulmonary arterial pressure greater than 30 mmHg is associated with increased mortality.
Winrevair 'overwhelming' at treating advanced PAH in Phase 3 trial
2024年11月27日 · Winrevair (sotatercept-csrk) significantly reduced the risk of all-cause death, a lung transplant, or hospitalization among adults with pulmonary arterial hypertension (PAH) at a high risk of dying enrolled in a Phase 3 clinical trial.
Funding to advance novel PAH treatment from Australian scientists
2024年10月23日 · New funding from Biocurate will support a Monash University project that's developing a novel disease-modifying treatment for PAH.
FDA approves sotatercept, now Winrevair, to treat PAH in adults
2024年3月27日 · The FDA approved under-the-skin injection therapy sotatercept, now Winrevair, for adults in the U.S. with pulmonary arterial hypertension.
Including Uptravi early in PAH treatment lowers hospitalization risk
2024年11月8日 · Adding Uptravi (selexipag) to standard-of-care PAH treatment within six months may reduce the risk of hospitalization, per a study.
Adverse long-term outcomes in PAH are associated with high …
2024年12月6日 · The connection between PAH and blood sugar may be conveyed through pulmonary vascular remodeling, showing SHR as an indicator of risk.
Pulmonary Venous Hypertension (PVH) - Pulmonary Hypertension …
2021年6月29日 · Looking for information about pulmonary venous hypertension? PVH's causes, symptoms, diagnosis, and treatments are highlighted here.
Pulmonary Hypertension News – Pulmonary Hypertension News
2025年1月13日 · Stopping antidepressants during pregnancy tied to lower PPHN risk Discontinuing antidepressants during pregnancy might reduce the risk of persistent pulmonary hypertension of the newborn (PPHN) and hospitalization, a Danish study suggests. “However, the reduced risk for newborns should be considered in light of the potential risks associated with untreated maternal depression, which may ...
Study links stopping Tyvaso to risk of disease worsening
2024年9月11日 · Tyvaso is well tolerated by PH patients with different types, and stopping raises by five times the risk of disease worsening, per a study.
Approval of new treatments for pulmonary hypertension prompts...
2024年4月3日 · After the FDA's approval of two new treatments for pulmonary hypertension, columnist Jen Cueva wonders if the drugs will be accessible to all.